Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 12.

Journal Article

Ahmad, A. R., Tho, L. M., Chik, Y. K. J., Lee, W. C. K., Yang, T-Y., Le, X., Eisert, A. K., Himpe, U., De Bondt, C., Mazieres, J., Petrini, I., Lam, W-S., Joshi, K., Berghoff, K., Vlassak, S., Karachaliou, N., Van der Wekken, A. J. and Hsia, T-C. (2022). Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series. Ann. Oncol., 33. S. S1584 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Eberhardt, W. E. E., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J. and Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063. Oncol. Res. Treat., 40. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262

Janne, P. A., van den Heuvel, M., Barlesi, F., Cobo, M., Mazieres, J., Crino, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., Poltoratskiy, A., Mariani, G., Ghiorghiu, D., Kilgour, E., Smith, P., Kohlmann, A., Carlile, D., Lawrence, D., Bowen, K. and Vansteenkiste, J. F. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Lena, H., Rizvi, N. A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M. A. and Ramalingam, S. (2016). Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J. Thorac. Oncol., 11 (4). S. S115 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Mazieres, J., Novello, S., De Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V. and Oh, I. (2017). Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC. J. Thorac. Oncol., 12 (11). S. S1897 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H. K., Das-Gupta, A. and Wolf, J. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann. Oncol., 29 (6). S. 1409 - 1417. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeiter, A., Cardona, A., Balas, B., Johannsdottir, H., Das-Gupta, A. and Wolf, J. (2017). Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Wolf, J., Helland, A., Oh, I-J, Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V and Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029

Wolf, J., Oh, I-J., Mazieres, J., de Castro, J., Revil, C., Kotb, A., Johansdottir, H., Zeaiter, A. and Novello, S. (2016). ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

de Castro, J., Novello, S., Mazieres, J., Oh, I-J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., de Marinis, F., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H., Chlistalla, M., Smoljanovic, V. and Wolf, J. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Thu Dec 7 08:02:15 2023 CET.